Global Market Study on E-Clinical Solution Software: Asia to Witness Highest Growth by 2020

Global Market Study on E-clinical Solution Software: Asia to Witness

Highest Growth by 2020

Persistence Market Research

Global E-Clinical Solution Software Market

Will Reach US$ 6,515.3 million in

2020:Persistence Market Research

Persistence Market Research

1

Global Market Study on E-clinical Solution Software: Asia to Witness

Highest Growth by 2020

Persistence Market Research Released New Market Report “Global Market Study on EClinical Solution Software: Asia to Witness Highest Growth by 2020”, the global eclinical solution software market was valued at US$ 3,005 Mn in 2014 and is expected to

expand at a CAGR of 13.8% from 2014 to 2020, to reach US$ 6,515.3 Mn by 2020.

Browse the full report at : http://www.persistencemarketresearch.com/market-research/eclinical-solution-market.asp

The global e-clinical solution software market is witnessing significant growth due to

increasing clinical trials and R&D investments in pharmaceuticals and life science sectors.

Increasing prevalence of diseases across the world is leading to rise in number of clinical

trials. Various lifestyle-associated diseases and genetic disorders in the Middle East and

North Africa have also led to increase in clinical trials in the respective regions. In addition,

the pharmaceutical industry is facing immense pressure to reduce the time consumed to

conduct clinical trials and increase effect of drugs. Presence of various end users such as

pharmaceuticals, clinical research organizations (CROs), and healthcare providers has

increased the demand for e-clinical solution software. The global e-clinical solution software

market was valued at US$ 3,005 Mn in 2014 and is expected to expand at a CAGR of 13.8%

from 2014 to 2020 to reach US$ 6,515.3 Mn by 2020.

Request Sample Report: http://www.persistencemarketresearch.com/samples/2884

In North America, the average cost of research and development for a successful

pharmaceutical drug continues to increase from pre-clinical stage i.e. initial...